The forecast Evamist numbers have been reached
Actually, Evamist sales are running at about 5% of expected peak, so far, which is not very good more than a year after the product's launch. Evamist has been a serious disappointment, so far.
I stand by my argument that its breadth of products makes Acrux a better defensive investment than most biotechs, but quite a bit now hinges on Axiron.
- Forums
- ASX - By Stock
- price action
The forecast Evamist numbers have been reachedActually, Evamist...
Featured News
Add ACR (ASX) to my watchlist
|
|||||
Last
6.3¢ |
Change
-0.002(3.08%) |
Mkt cap ! $18.31M |
Open | High | Low | Value | Volume |
6.6¢ | 6.6¢ | 6.3¢ | $5.23K | 80.08K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 249878 | 6.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.5¢ | 73455 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 249878 | 0.063 |
1 | 16145 | 0.062 |
1 | 70000 | 0.061 |
1 | 70000 | 0.060 |
1 | 92500 | 0.052 |
Price($) | Vol. | No. |
---|---|---|
0.065 | 73455 | 1 |
0.070 | 50000 | 1 |
0.072 | 47301 | 1 |
0.073 | 15000 | 2 |
0.075 | 149999 | 1 |
Last trade - 15.55pm 05/07/2024 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |